Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7790434 | 0.83 | L3MBTL1 (0.53) | L3MBTL1TDP1MAPTGAAPOLB | |
| SCHEMBL7790446 | 0.76 | FDPS (0.55) | CRHR1 | |
| SCHEMBL7794298 | 0.76 | FDPS (0.60) | L3MBTL1TDP1TSHRMAPTHTT | |
| SCHEMBL8407752 | 0.73 | L3MBTL1 (0.40) | CRHR1L3MBTL1TDP1MAPTGAA | |
| SCHEMBL7793613 | 0.70 | L3MBTL1 (0.45) | L3MBTL1MAPTPOLBMEN1KMT2A | |
| SCHEMBL8007654 | 0.70 | CRHR1 (0.48) | CRHR1TDP1MAPTGAAPOLB | |
| SCHEMBL8166679 | 0.68 | FDPS (0.62) | L3MBTL1TSHRMAPTGAAPOLB | |
| SCHEMBL12909531 | 0.68 | KMT2A (0.50) | CRHR1L3MBTL1TDP1MAPTGAA | |
| SCHEMBL5359859 | 0.67 | TSHR (0.42) | TSHRMAPTGAAPOLBMEN1 | |
| SCHEMBL7790467 | 0.67 | POLB (0.40) | GAAPOLBMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0762883-B1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 2001-11-14 | — | — | EP | claimed |
| EP-0762883-A1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 1997-03-19 | — | — | EP | claimed |
| WO-1995033466-A1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 1995-12-14 | — | — | WO | claimed |
| EP-0762883-B1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 2001-11-14 | — | — | EP | disclosed |
| US-6083938-A | TREATING BONE DISEASES SELECTED FROM THE GROUP CONSISTING OF OSTEOLYTIC BONE DISEASES DUE TO MALIGNANCY, PAGET'S DISEASE AND PRIMARY AND SECONDARY OSTEOPOROSIS | LEIRAS OY (FI) | 2000-07-04 | — | — | US | disclosed |
| US-5866556-A | BONE DISORDERS | LEIRAS OY (FI) | 1999-02-02 | — | — | US | disclosed |
| EP-0762883-A1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033466-A1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 1995-12-14 | — | — | WO | disclosed |